Abstract
Porphyria cutanea tarda (PCT) is the most common form of human porphyria, due to reduced activity of uroporphyrinogen decarboxylase (UROD). There are many factors which can trigger PCT such as viral infections, excessive alcohol intake, iron overload, hepatotoxic drugs and hepatic tumours. Drug induced PCT is well documented but PCT induced by interferon α has rarely been described and only in cases of Hepatitis C Virus (HCV) infection or haematological malignancies.
Here, we report the first case of de novo PCT induced by adjuvant interferon α (IFNα) therapy in a patient with stage II melanoma.Current Drug Safety
Title:Sporadic Porphyria in a Patient with Stage II Melanoma Treated with Interferon α
Volume: 12 Issue: 2
Author(s): V. Reymann*, C. Girard, O. Dereure, B. Guillot and A. Du Thanh
Affiliation:
- Dermatology Department,CHU St Eloi, Montpellier,France
Keywords: Interferon, porphyria, melanoma, PCT, UROD, HCV.
Abstract: Porphyria cutanea tarda (PCT) is the most common form of human porphyria, due to reduced activity of uroporphyrinogen decarboxylase (UROD). There are many factors which can trigger PCT such as viral infections, excessive alcohol intake, iron overload, hepatotoxic drugs and hepatic tumours. Drug induced PCT is well documented but PCT induced by interferon α has rarely been described and only in cases of Hepatitis C Virus (HCV) infection or haematological malignancies.
Here, we report the first case of de novo PCT induced by adjuvant interferon α (IFNα) therapy in a patient with stage II melanoma.Export Options
About this article
Cite this article as:
Reymann V.*, Girard C., Dereure O., Guillot B. and Du Thanh A., Sporadic Porphyria in a Patient with Stage II Melanoma Treated with Interferon α, Current Drug Safety 2017; 12 (2) . https://dx.doi.org/10.2174/1574886312666170502163628
DOI https://dx.doi.org/10.2174/1574886312666170502163628 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Apoptosis Pathways in Cancer Therapy
Current Cancer Drug Targets Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation
Current Drug Metabolism Isolation and Boactivities of Furfuran Type Lignan Compounds from Edible Plants
Recent Patents on Food, Nutrition & Agriculture A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Rapid Estrogen Signaling in Spermatogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) c-Myc: Linking Transformation and Genomic Instability
Current Molecular Medicine Actively Targeted Nanoparticles for Drug Delivery to Tumor
Current Drug Metabolism Small-Molecule CSF1R Inhibitors as Anticancer Agents
Current Medicinal Chemistry Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors
Current Medicinal Chemistry Stereotactic Body Radiotherapy in the Management of Head and Neck Malignancies
Current Cancer Therapy Reviews Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design The Diagnosis of Large Airway Pathology and the Role of Rigid Bronchoscopy
Current Respiratory Medicine Reviews New and Emerging Antiresorptive Treatments in Osteoporosis
Current Drug Safety Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
Current Medicinal Chemistry Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth Review
Current Medicinal Chemistry Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Differentiation Between Osteoporotic and Neoplastic Vertebral Fractures: State of The Art and Future Perspectives
Current Medical Imaging An Insight into Purine, Tyrosine and Tryptophan Derived Marine Antineoplastic Alkaloids
Anti-Cancer Agents in Medicinal Chemistry Transforming Cancer Epigenetics Using Nutritive Approaches and Noncoding RNAs
Current Cancer Drug Targets